Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Interatrial Shunt System Relieves Heart Failure Symptoms

By HospiMedica International staff writers
Posted on 19 Mar 2020
A novel interatrial shunt controls elevated left atrial pressure (LAP) in order to prevent pulmonary congestion and hospitalizations in chronic heart Failure (HF) patients.

The V-Wave (Caesarea, Israel) Ventura shunt system is composed of a miniature biocompatible interatrial implant and a dedicated delivery system. More...
The implant is designed to regulate LAP by straddling the interatrial septum and forming a conduit that connects left and right atria, allowing continuous, dynamic decompression of the left atrium at rest and physical activity. The device is placed through the fossa ovalis in a minimally invasive cardiac catheterization procedure, using the proprietary delivery catheter.

The Ventura Interatrial Shunt is being evaluated in a global, randomized, controlled, double-blinded, 500 patient pivotal trial called RELIEVE-HF, which is designed to demonstrate safety and effectiveness of shunt therapy in reducing HF morbidity and mortality and improving functional status. The study is enrolling advanced HF patients with preserved or reduced left ventricular ejection fraction (LVEF) who remain symptomatic, despite the use of guideline-directed medical and device therapies. Approximately 100 of the top hospitals in North America, Europe, and Israel are or will be participating.

“More than 26 million people suffer from chronic heart failure worldwide, and HF remains a leading driver of disability and acute hospitalization, particularly in the growing elderly population,” said William Abraham, MD, chief medical officer at V-Wave. “The minimally invasive implanted Ventura interatrial shunt relieves excessive pressure in the left side of the heart, thereby reducing the build-up of fluid in the lungs, which is the most common reason for worsening HF symptoms, exercise limitation, and HF hospitalizations.”

There are two types of HF; HF with reduced ejection fraction (HFrEF, systolic heart failure), and heart failure with preserved or mid‐range ejection fraction (HFpEF/HFmrEF), previously called diastolic heart failure. HFpEF accounts for approximately 50% of all HF, but treatment options are limited, consisting mainly of diuretics and fluid balance control. Although the pathophysiology of HFpEF is complex, many of the symptoms are a result of excessive rises in LAP, in particular during exercise.

Related Links:
V-Wave


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Vessel Sealing Instrument
ERGOseal
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Masimo smartSET pulse oximetry with PPG AFib and OIRD Detection (Photo courtesy of Masimo)

Smart Pulse Oximetry Supports Earlier Recognition of Arrhythmias and Respiratory Risk

On general care floors, respiratory compromise and arrhythmias can develop between routine checks. Atrial fibrillation often goes undiagnosed in older adults, while opioid-induced respiratory depression... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: Brain PET imaging could help identify Alzheimer’s patients most likely to benefit from available therapies (Image Credit: iStock)

Amyloid and Tau PET Guide Selection and Monitoring of Alzheimer’s Therapy

Alzheimer’s disease is the most common form of dementia and can be difficult to distinguish from other causes of cognitive decline. According to the World Health Organization (WHO), 57 million people were... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.